# Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

> **NCT05714371** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 618 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab + nivolumab
- **DRUG:** Pembrolizumab
- **DRUG:** Dabrafenib + trametinib

## Key facts

- **NCT ID:** NCT05714371
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-02
- **Primary completion:** 2022-01-27
- **Final completion:** 2022-01-27
- **Target enrollment:** 618 (ACTUAL)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05714371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05714371, "Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05714371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*